Representative Jefferson Shreve (R-Indiana) recently sold shares of Pfizer Inc. NYSE: PFE. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $15,001 and $50,000 in Pfizer stock on April 11th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.
Representative Jefferson Shreve also recently made the following trade(s):
- Purchased $50,001 - $100,000 in shares of Chipotle Mexican Grill NYSE: CMG on 4/17/2025.
- Purchased $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Caterpillar NYSE: CAT on 4/17/2025.
- Sold $15,001 - $50,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Western Digital NASDAQ: WDC on 4/17/2025.
- Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Stryker NYSE: SYK on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Ross Stores NASDAQ: ROST on 4/17/2025.
Pfizer Price Performance
Pfizer stock traded down $0.69 during trading hours on Friday, hitting $22.28. 38,991,216 shares of the stock were exchanged, compared to its average volume of 40,524,410. The stock has a market capitalization of $126.67 billion, a P/E ratio of 15.80, a P/E/G ratio of 0.64 and a beta of 0.58. The business's 50-day moving average is $24.02 and its two-hundred day moving average is $25.52. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the prior year, the company earned $0.82 EPS. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.72%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is currently 124.64%.
Hedge Funds Weigh In On Pfizer
Several hedge funds have recently added to or reduced their stakes in the stock. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $27,000. Gould Capital LLC increased its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the 4th quarter worth approximately $28,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on PFE. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $29.17.
Check Out Our Latest Stock Analysis on Pfizer
Insiders Place Their Bets
In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company's stock.
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
